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Abstract: Artificial sweeteners (AS) are synthetic sugar substitutes that are commonly consumed in
the diet. Recent studies have indicated considerable health risks which links the consumption of
AS with metabolic derangements and gut microbiota perturbations. Despite these studies, there is
still limited data on how AS impacts the commensal microbiota to cause pathogenicity. The present
study sought to investigate the role of commonly consumed AS on gut bacterial pathogenicity and
gut epithelium-microbiota interactions, using models of microbiota (Escherichia coli NCTC10418 and
Enterococcus faecalis ATCC19433) and the intestinal epithelium (Caco-2 cells). Model gut bacteria
were exposed to different concentrations of the AS saccharin, sucralose, and aspartame, and their
pathogenicity and changes in interactions with Caco-2 cells were measured using in vitro studies.
Findings show that sweeteners differentially increase the ability of bacteria to form a biofilm. Co-
culture with human intestinal epithelial cells shows an increase in the ability of model gut bacteria
to adhere to, invade and kill the host epithelium. The pan-sweet taste inhibitor, zinc sulphate,
effectively blocked these negative impacts. Since AS consumption in the diet continues to increase,
understanding how this food additive affects gut microbiota and how these damaging effects can be
ameliorated is vital.
Keywords: artificial sweeteners; microbiota; in vitro models; gut bacteria
1. Introduction
There are more than 100 trillion microbes in the gut which encode hundredfold more
unique genes than the human genome [1,2]. There is a continued, concerted effort to fur-
ther understand this, for example, with the METAgenomics of the Human Intestinal Tract
collaborative project which investigates the contribution of the microbiome in providing
unique protein coding genes at levels which are 360 times greater than their host [3,4]. The
gut microbiome is in close proximity to the intestinal epithelium and, as such, epithelial
cells of the intestine are exposed to diverse antigenic substances from both dietary com-
ponents and gut microbiota activities. Indeed, the importance of commensal microbiota
for intestinal epithelial function has already been demonstrated in germ-free mice which
display a significant reduction in mucosal layer thickness and antimicrobial product lev-
els [5–7]. Microbial metabolites from the gut microbiota, such as short-chain fatty acids
(SCFA), indole, and lactate have also been shown to regulate intestinal barrier function [8,9].
Higher SCFA concentrations have been linked with increased gut dysbiosis, gut permeabil-
ity and are indicators of various metabolic diseases, whilst improved microbial diversity
showed opposite correlation with these outcomes [10]. Therefore, the gut microbiota, and
associated metabolic products, play a significant role in intestinal health and wellbeing of
the host.
There is a symbiotic relationship between microbiota and host where metabolic prod-
ucts of gut microbiota, such as B group vitamins and vitamin K, provides essential support
for human growth and development [11]. However, diet is also one of the most important
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factors that shapes gut microbiota. Studies have demonstrated that a diet which is low
in fat and animal protein but rich in complex carbohydrates provides the host with a
more diverse, and therefore “healthy”, gut microbiome [12]. Adult healthy volunteers
who consumed a large amount of animal-based diet displayed a shift in bacterial phyla
composition associated with increased presence of the bile-tolerant enterotypes (Alistipes,
Bilophila, and Bacteroides) and decreased the quantities of Firmicutes that metabolize plant
polysaccharides (Roseburia, Eubacterium rectale, and Ruminococcus bromii) in the gut micro-
biota [13]. Similar observations were found comparing the intestinal microbiota of children
in a rural village in Africa with an urban area in Europe, where composition of diet is
dramatically impacted by the Western diet [14]. Whilst these studies demonstrate a change
in bacterial phyla following long-term changes in diet, short-term exposure of healthy indi-
viduals to an energy-rich diet have been found to affect the function of the gut microbiota
with negative changes observed in bacterial secretion system, protein export, and lipoic
acid metabolism [12]. Interestingly, it is not only key food groups which impact on the
gut microbiota. Studies demonstrate that additives, typically used to improve the taste,
appearance and longevity of foods and drinks, also have an impact on the composition
and function of gut bacteria [5,15]. For example, the FDA-approved dietary emulsifiers
carboxymethyl cellulase and polysorbate 80, when administered to mice at acceptable
daily intake levels, increase the number of mucolytic bacteria, and decrease the number
of Bacteroidetes in the gut microbiota [5]. These changes result in a reduced colonic mucin
layer and, as such, several studies have demonstrated the association between emulsifier
exposure and metabolic syndrome development [5]. Therefore, there is a well-established
link between dietary additives, dysregulation of microbiota, and subsequent impact on
gut health.
In recent years, artificial sweeteners have become popular as a non-caloric additive to
sweeten foods and drinks. Artificial sweeteners, such as sucralose and aspartame, provide
the sweet taste in low-calorie foods, which have increased their popularity worldwide [16].
As these sweeteners are cheap, easily available, and result in enhanced food flavour, they
have been incorporated into many food products and beverages, as well as pharmaceutical
products. Epidemiological studies have evidenced the beneficial role of sweeteners in
weight loss and for people suffering from glucose intolerance and type 2 diabetes melli-
tus [16–18]; there are, however, studies which indicate opposing results. Using animal and
human studies, artificial sweetener consumption has been linked with conditions lead-
ing to metabolic disease development [15]. Indeed, sweeteners were reported to induce
glucose intolerance by altering the composition and function of the gut microbiota. In
mice, sweetener-intake was linked with dysbiosis leading the host to be prone to symp-
toms related to metabolic disease. These symptoms were abrogated by treatment with the
antibiotics, ciprofloxacin, metronidazole, and vancomycin, which affected the commensal
microbiota and ameliorated the metabolic disease symptoms [14]. Further studies have
confirmed that aspartame exposure, over 8 weeks, increases fasting glucose levels and
insulin intolerance in rats [18]. These studies show that perturbed gut microbiota occurred,
in response to sweetener treatment, with an increase in abundance of Enterobacteriaceae and
Clostridium leptum. In a human study on 4-day food intake, the relationship between aspar-
tame and acesulfame potassium intake and microbiota was demonstrated; no differences
in the abundance and genetic composition of bacteria were noted between the artificial
sweetener consumers and non-consumers, however, a significant difference in microbial
diversity was observed [19]. Bian et al. demonstrated that numerous pro-inflammatory
mediators were potentially produced by gut bacteria following the consumption of sweet-
eners in the diet, which is associated with other metabolic disease conditions like diabetes
and obesity [20,21]. Interestingly, in gut epithelial cells, our recent studies demonstrate that
exposure to artificial sweeteners increases apoptosis and permeability across the intestinal
epithelium associated with inflammatory gut leak [22]. Despite controversy in the field,
there is strong evidence that without changing the bacterial composition, artificial sweeten-
ers in the diet cause changes in bacterial diversity, and potentially pathogenicity, which
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is likely to exert a negative impact to the host. However, how artificial sweeteners affect
symbiotic bacteria and contribute to pathogenicity remained veiled yet.
Escherichia coli (E.coli) is the most frequent facultative anaerobic Gram-negative bac-
terium inhabiting the human GI tract and is a versatile pathogen whilst Enterococcus
faecalis (E. faecalis) is a facultative anaerobic, Gram-positive coccus that inhabits the human
GI tract [23,24]. Both E. coli and E. faecalis are commensal, as well as pathogens, and
both colonise immediately after birth so are good representatives of their corresponding
phyla [25]. From a technical perspective, both species can be isolated easily, grown, and
maintained in the laboratory and are frequently used as potential human faecal indicators.
We therefore used E. coli and E. faecalis as models to test our hypothesis that artificial
sweeteners, at physiologically achievable levels in the small intestine [22,26], negatively
impact bacteria in the gut microbiome. In the gut environment, both human epithelial cells
and the microbiota are exposed to various concentrations of artificial sweeteners when
consumed in the diet. We sought to understand the effect of commonly consumed artificial
sweeteners, saccharin, sucralose, and aspartame, on two model gut bacteria (E. coli and
E. faecalis) to gain an insight into the potentially pathogenic mechanisms through which
sweeteners could impact the microbiota.
2. Results
2.1. Only the Artificial Sweetener Saccharin Affects E. coli Model Gut Bacteria Growth at
High Concentrations
The effect of artificial sweeteners on E. coli and E. faecalis growth in planktonic culture
was measured every 12-h, upon exposure to varying concentrations of artificial sweetener
(saccharin, sucralose, and aspartame), for 4 days. Experiments with E. coli showed no
significant change in normalised growth in response to sucralose or aspartame exposure at
any time point or concentration (Figure 1b or c). In contrast, exposure to 1000 µM saccharin
significantly reduced E. coli growth between 48–84 h, however lower concentrations of
saccharin had no impact on E. coli growth (Figure 1a). Experiments with E. faecalis demon-
strated no significant effect of either saccharin, sucralose, or aspartame, on normalised
bacteria cell growth, at any time point or concentration (Figure 1d–f).
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Fig re 1. nly the artificial sweetener saccharin affects E. coli model gut bacteria growth at high
. E. coli (panels a–c) and E. f ecalis (panels d–f) growth was measured, following
rtificial s eeteners (0 to 1 0 µM), sa charin (panels a,d), sucralose (panels b,e),
and aspartame (panels c,f), for up to 96 h. Specific bacteria for each study are included in underlined
text. Data are presented as mean ± standard error mean (S.E.M.). * p < 0.05 versus 0 µM at the same
time point.
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2.2. Artificial Sweeteners Differentially Increase Biofilm Formation, but Not Haemolytic Activity,
in the Two Model Gut Bacteria
The ability for artificial sweeteners to regulate the pathogenicity of model gut bacteria
was studied by measuring biofilm formation and haemolytic activity assays. Experiments
were performed with E. coli and E. faecalis exposed to saccharin, sucralose, or aspartame
at the physiological concentration of 100 µM; the sweeteners did not impact bacteria cell
growth, except as seen with E. coli and saccharin at 1000 µM (Figure 1a). Biofilm formation
of E. coli was significantly increased, compared to the vehicle control, when bacteria were
exposed to artificial sweeteners saccharin, sucralose, and aspartame (Figure 2a). Whilst
biofilm formation of E. faecalis was also increased with all three artificial sweeteners, only
aspartame exposure caused a significant increase in the ability of E. faecalis to form a biofilm
(Figure 2b). In contrast, the haemolysis assay indicated that artificial sweeteners saccharin,
sucralose, and aspartame had no effect on qualitative (Figure 2c (i)) or semi-quantitative
(Figure 2c (ii)) haemolysin production of either E. coli or E. faecalis, in contrast to the positive
control, the haemolytic bacteria S. aureus.
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Figure 2. Artificial sweeteners differentially increase biofilm formation, but not haemolytic activity,
in the two model gut bacteria. E. coli (panel a) and E. faecalis (panel b) were exposed to artificial
sweeteners, saccharin, sucralose, and aspartame (100 µM) for 24 h (panels a,b) or 48 h (panel c)
and biofilm formation or haemolysis assay, respectively, were performed. For the haemolysis assay,
S. aureus was used as a positive control to show haemolysin release (panel c) using representative
images (panel c (i)) and semi-quantification (panel c (ii)) of haemolysi . Specific bacteria for each
study are included in underlined text. Data are present d as me n ± S.E.M for panel and b and as
mean only for panel c. * p < 0.05 versus vehicle for biofilm formation.
2.3. rtificial S eeteners Significantly isrupt the Interaction bet een odel ut Bacterial and
Intestinal Epithelial Cells
To further understand the physiological effect of artificial sweeteners on model gut
bacteria, E. coli and E. faecalis, the next studies used a co-culture system with the intestinal
epithelial cell line, Caco-2 cells. Studies measured the effect of saccharin, sucralose, and
aspartame in regulating the ability of model gut bacteria to adhere to, invade, and kill
intestinal epithelial cells.
Intact E. coli or E. faecalis, which were pre-exposed to artificial sweeteners, were
incubated with Caco-2 cells to establish adhesion ability of the model gut bacteria. All three
artificial sweeteners studied, saccharin, sucralose, and aspartame, significantly increased
adhesion of both E. coli and E. faecalis to intestinal epithelial cells (Figure 3a,d). Interestingly,
a more dramatic fold-increase in bacterial adhesion to Caco-2 cells was observed with
E. faecalis compared to E. coli for saccharin (E. coli 2.3 ± 0.4 versus E. faecalis 5.2 ± 2.1),
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sucralose (E. coli 2.0 ± 0.3 versus E. faecalis 5.4 ± 1.8), and aspartame (E. coli 2.9 ± 0.7 versus
E. faecalis 6.6 ± 1.9).
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The ability of model gut bacteria, E. coli and E. faecalis, to invade Caco-2 cells was
measured following exposure to artificial sweeteners. Sucralose and aspartame expo-
sure significantly increased the invasion index of both E. coli and E. faecalis (Figure 3b,e).
In contrast, incubation with saccharin had a significant effect on the invasive ability of
E. faecalis (Figure 3e) but not E. coli (Figure 3b). Soluble bacterial factors released from
E. coli or E. faecalis exposed to artificial sweeteners were incubated with Caco-2 cells and
cytotoxicity was measured. Soluble factors secreted from E. coli exposed to saccharin and su-
cralose, but not aspartame, induced a small but significant reduction in Caco-2 cell viability
(Figure 3c). In contrast, E. faecalis exposed to sucralose and aspartame, but not saccharin,
released soluble factors which significantly lowered Caco-2 cell viability (Figure 3f).
2.4. Artificial Sweeteners Impact Model Gut Bacteria through a Taste Sensing Mechanism
Our final experiments sought to understand how artificial sweeteners regulated the
model gut bact ria pathogenic functi ns studied: biofilm formation, adhesion and invasion
ability, and cytotoxicity. Given the lack of published literature in the fi ld, there is no
specific taste recept r established in bacteria. The pan taste inhibitor, zinc sulp at , was
used to establish the potential of a taste sensing mechanism in E. coli and E. faecalis [27]. At a
range of concentrations, zinc sulphate has no impact on growth of either model gut bacteria
(Figure 4a). Zinc sulphate also had no impact on biofilm formation, adhesive or invasive
ability of either bacteria in the absence of sweeteners (vehicle-treated E. coli or E. faecalis)
(Figure 4b–g). In E. coli, zinc sulphate significantly reduced sweetener-induced biofilm
formation (Figure 4b) and adhesive ability (Figure 4c). Furthermore, aspartame- and
sucralose-mediated increase in the ability of E. coli to invade Caco-2 cells was attenuated
by zinc sulphate (Figure 4d). In E. faecalis, zinc sulphate attenuated biofilm formation
induced by aspartame (Figure 4e) and all sweetener-induced effects on bacterial adhesion
and invasion of Caco-2 cells (Figure 4f,g). The cytotoxic effect on Caco-2 cells, induced
by saccharin and sucralose exposure with E. coli (Figure 3c) and sucralose and aspartame
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exposure with E. faecalis (Figure 3f), was also blocked by exposure to zinc sulphate (data
not shown).
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Taken together, findings demonstrate the effect of artificial sweeteners, saccharin,
sucralose, and aspartame, in increasing the pathogenicity of model gut bacteria, E. coli and
E. faecalis, through a taste-dependent pathway. Further studies are needed to understand
the molecular mechanisms responsible for these pathogenic effects with the aim of reducing
the negative impact of sweeteners on gut health.
3. Discussion
Artificial sweeteners are commonly consumed in the diet as an aid for weight loss
however there is still controversy on the potential benefits versus detrimental effects
of these compounds on gut health. Previous studies have demonstrated the impact of
sweeteners on diversity of gut microbiota [15,19,28]. These studies indicate an increase in
bacteria, such as Enterobacteriaceae, of which E. coli is one, however this has been studied
in whole microbiome rather than at the individual bacteria or molecular level. In the
present study, we use an in vitro model of the gut and the icrobiota to investigate the
impact of sweeteners on potential changes in pathogenicity. Our studies demonstrate that
saccharin, sucralose, and aspartame at the physiological concentration of 100 µM, which
could be easily achieved in the diet [15,22], differentially increase biofilm formation as
well as the ability of bacteria to adhere to, invade and kill mam alian gut epithelial cells.
These findings indic te that sacch rin, sucralose, and aspartame all promote pathoge ic
changes in two model gut bacteri , E. coli and E. faecalis, which could w rs the effect of
consuming artificial sweeteners in the diet on gut health.
Bacterial growth is one of the most well-studied characteristics of metabolism. Plank-
tonic growth of E. coli and E. faecalis showed little effect from exposure to artificial sweeten-
ers at a range of concentrations. The exception to this is saccharin at 1 mM concentration
which caused bacteriostatic effects in E. coli from 48 to 84 h. These findings differ from those
in the literature where Wang et al. established that saccharin, sucralose, and acesulfame K
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have bacteriostatic effects on E. coli HB101 and K-12 strains [29]. Importantly, this study was
performed with supraphysiological sweetener concentrations in the 30–80 mM range which
may explain the difference in findings [16]. Our studies also demonstrate that all three
sweeteners evaluated (saccharin, sucralose, and aspartame) increased biofilm formation
of E. coli with only aspartame affecting biofilm formation of E. faecalis. Bacteria typically
transition from planktonic to biofilm as a result of environmental and physiological cues,
including cell density, nutrient availability, and cellular stress. Bacteria growing in biofilms
are less sensitive to antimicrobial resistance treatment and are more likely to express more
virulence factors and exotoxins compared to planktonic cells [30–32]. These virulence
factors may be related to those causing increased adhesion to and invasion of Caco-2
cells and elevated cytotoxic effects, as we observed in the present study. It is, however,
worth noting that we did not note the same pattern of sweetener effect for the different
pathogenicity measurements made for each bacterium. For example, in studies with E.
coli we established that all 3 sweeteners studied cause an increase in biofilm formation
and adhesion to Caco-2 cells. However, only sucralose and aspartame affected bacterial
invasion and soluble factors from only saccharin- and sucralose-treated E. coli decreased
Caco-2 cell viability. Therefore, sweeteners have differential effects on pathogenicity in E.
coli and E. faecalis.
There are a range of virulence factors which bacteria can utilise to become pathogenic
to a host, such as prevention of complement activation and escape from phagosomes.
Some pathogenic E. coli have been shown to display a range of virulence factors, such
as bundle-forming pilus (BFP), type 1 pili and cytolysin A (ClyA), to cause adherence
and invasion of host cells, and the production of cytotoxins which kill host cells [33–35].
Similarly, pathogenic E. faecalis shows adhesion and invasion of intestinal epithelial cells,
via pili and aggregation substances, such as AsaI and glycolipids, and cytotoxicity via
secreted factors, such as cytolysin [36–39]. Other mechanisms of pathogenicity have also
been identified. E. coli can exert pathogenic effects, such as biofilm formation, through yafK
and Fis gene expression, and α- or β-haemolysis, potentially through a ClyA-mediated
pathway [40,41]. Similarly, biofilm formation and haemolysis activity have been shown
in pathogenic E. faecalis by the xdh or Esp genes and β-haemolysin, respectively [42–44].
Whilst artificial sweeteners have been shown to affect dysbiosis in the gut microbiota, there
are limited mechanistic studies which show pathogenic responses of individual bacteria to
sweeteners. In the present study, we demonstrate that the artificial sweeteners saccharin,
sucralose, and aspartame, at physiological concentrations, impact on all these pathogenic
mechanisms except β-haemolysis. The model bacteria, E. coli and E. faecalis, are α- and
γ-haemolytic, respectively, in normal conditions, however, they can turn into β-haemolytic
when pathogenic [44,45]. It is possible that we noted no change in haemolysis because of
the in vitro nature of the study or the use of laboratory strains of each bacteria. Indeed,
clinical isolates of E. coli or E. faecalis have been shown to display haemolytic genes, such
as hly and ClyA [46,47], which are likely to be lacking from the bacteria we studied. It
is also worth noting that model gut bacteria were exposed to artificial sweeteners for
24 h, so only the long-lasting response to the additive was recorded. However, given that
artificial sweeteners are consistently present in the diet, in a range of sources from food,
drink, and cosmetics, it is likely that the microbiome would be continuously exposed and
long-lasting responses are most accurate to study. Further study on the genetic changes of
each bacteria, following exposure to saccharin, sucralose, and aspartame, may provide a
deeper molecular understanding of the mechanisms regulating their pathogenicity.
In mammals, sweet taste molecules are recognised via the sweet taste receptor hetero-
or homo-dimer, T1R2/T1R3 or T1R3/T1R3, respectively [48]. Zinc sulphate is a potent
inhibitor of sweet taste sensing which is hypothesised to act through the zinc ion binding
to T1R2/T1R3 or T1R3/T1R3 and altering the conformation of the receptor to prevent
sweeteners from interacting with it [27]. Our studies demonstrate that zinc sulphate can
effectively block the impact of sweeteners on pathogenicity for both E. coli and E. faecalis.
This indicates the presence of a sweet taste sensor in bacteria through which sweeteners can
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activate pathogenic effects, however, sucralose has a perceived sweet taste intensity which
is 2-times higher than saccharin and 3-times higher than aspartame [49]. Our findings
demonstrate differential effects of the three sweeteners on biofilm formation, adhesion
and invasion, and cytotoxicity in E. coli and E. faecalis. Therefore, it is likely that these
bacteria are responding independently of traditional taste sensing pathways. Indeed, whilst
studies indicate the potential for olfactory responses in Bacillus licheniformis, there is no
literature indicating the presence of a sweet taste receptor or sensor in bacteria which could
respond to artificial sweeteners [50]. Instead, there is evidence that sweeteners can cause
DNA damage in bacteria, elevate bacterial mutation rate in a dose-dependent manner
or ROS production and detoxification, and increase cell membrane permeability [51–54].
ROS can modulate the quorum sensing ability of bacteria to sense and respond to their
environment [55,56] therefore sweeteners may impact pathogenicity of model gut bacteria
in the present study through a ROS-dependent pathway.
Bacteria such as E. faecalis have been shown to translocate across the intestinal wall,
disseminate into the blood stream, and cause septicaemia along with congregation in the
mesenteric lymph nodes, liver, and spleen [57–59]. In our present study, we demonstrate
that saccharin, sucralose, and aspartame increased the ability of model gut bacteria to
adhere to and invade intestinal epithelial cells, with the exception of saccharin which has no
significant effect on E. coli invasion. Furthermore, we and others have previously demon-
strated the negative effect of artificial sweeteners, saccharin, sucralose, and aspartame,
on intestinal epithelial cell apoptosis and permeability [22,60], thus further increasing the
opportunity for bacteria to traverse the gut epithelium and cause septicaemia. However, to
date, no studies have been performed to study the link between consumption of artificial
sweeteners correlates with incidence of septicaemia.
Globally, sweeteners (acesulfame, saccharin, and sucralose) have been detected in
wastewater, surface water, groundwater, and drinking water systems [61–63]. More wor-
ryingly, artificial sweeteners have been linked to increased horizontal transfer of antimi-
crobial resistance genes in environmental and clinical settings [52,54]. In addition, in-
creased biofilm formation is believed to cause medical device-associated infections and is
closely linked to the antibiotic-resistant bacteria, which is now a widespread public health
threat [64–67]. Understanding the role of sweeteners in regulating biofilm formation, as
well as other pathogenic effects on the intestinal epithelium and antimicrobial resistance of
bacteria, could have a dramatic impact on public health in a multitude of ways.
4. Materials and Methods
4.1. Materials
Enterococcus faecalis (E. faecalis, 19433™) and Escherichia coli (E. coli, 10418) were pur-
chased from ATCC (Middlesex, UK) and NCTC (Salisbury, UK), respectively. Staphylococcus
aureus, for use as positive control for the haemolysis assay, was a kind gift from Dr. Christo-
pher O’Kane (Anglia Ruskin University). Bacterial media and blood agar plates was
purchased from Oxoid (ThermoFisher, Hampshire, UK). For bacterial growth curve experi-
ment and biofilm assay, sterile, flat-bottom, non-treated polystyrene 96-well plates were
purchased from CytoOne (StarLabs, Milton Keynes, UK). Phosphate Buffered Saline (PBS)
was obtained from Gibco (ThermoFisher, Hampshire, UK). Human colon adenocarcinoma
cells (Caco-2, 86010202), Eagle’s Minimal Essential Media (EMEM), zinc sulphate, antibi-
otics, and artificial sweeteners (saccharin, sucralose, and aspartame) were purchased from
Sigma-Aldrich (Dorset, UK).
4.2. Bacterial and Mammalian Cell Culture
Bacterial cells were grown aseptically at 37 ◦C on solid media for single colonies, or in
liquid media with shaking (150 rpm) for growth measurements. Brain Heart Infusion agar
and Nutrient Agar were used as solid, and Brain Heart Infusion and Nutrient broth were
used as liquid media for E. faecalis and E. coli, respectively, as guided by the supplier.
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A human intestinal epithelial cell line, Caco-2 cells, was used for the interaction assays,
such as adhesion, invasion, and cytotoxicity assays. Monolayers of Caco-2 cells were
grown aseptically in EMEM supplemented with 10% foetal bovine serum and 1% antibiotic
(1 U/mL penicillin, 1 µg/mL streptomycin) solution at 37 ◦C in 5% CO2.
4.3. Growth Curve Determination
A single bacterial colony of E. coli or E. faecalis was inoculated aseptically into Nutrient
broth or Brain-heart infusion, respectively, supplemented with the artificial sweeteners,
saccharin, sucralose, and aspartame at ranging concentrations from 0.1 to 1000 µM, or
vehicle (double-distilled water (ddH2O)) and allowed to grow for up to 4 days. Growth
was recorded as absorbance at 600 nm (A600) using the VictorTM X3 (Perkin Elmer) and
values were normalised to 0 µM at 0 h (as 1).
4.4. Biofilm Formation Assay
Biofilm formation of E. coli and E. faecalis was measured after exposure to artificial
sweeteners, saccharin, sucralose, and aspartame (100 µM) using crystal violet biofilm
formation assay as described previously [68] with some modifications. A single bacterial
colony was inoculated into 10 mL of the corresponding liquid media supplemented with
sweetener or vehicle (H2O) in presence or absence of zinc sulphate. Absorbance at 600 nm
was measured on a VictorTM X3 multiplate reader to ensure equal bacterial cell numbers,
and overnight culture was transferred into liquid media (1:200) supplemented with artificial
sweeteners. After vortexing, 200 µL was transferred into sterile 96-well plasticware plates
and grown aerobically for 48 h at 37 ◦C. The supernatant was removed, and wells were
washed twice with ddH2O to remove loosely associated bacteria. Each well was stained
with 150 µL 0.1% Gram crystal violet for 20 min at room temperature. After staining,
wells were washed with ddH2O three times. The retained crystal violet by the biofilms
were brought into solution by adding 200 µL 30% acetic acid and incubating at 37 ◦C
for 5 min. The quantitative analysis of biofilm formation was performed by measuring
absorbance at 600 nm using the multiplate reader (VictorTM X3). The biofilm forming unit
was calculated by dividing the absorbance of crystal violet retained with the absorbance of
the total bacterial growth and was normalised to the control (as 1).
4.5. Haemolysis Assay Using Blood Agar Plates
Blood Agar plate with 7% Horse Blood was used to investigate the haemolytic proper-
ties of E. coli and E. faecalis after exposure to artificial sweeteners. Bacteria were exposed
to the artificial sweeteners, saccharin, sucralose, and aspartame (100 µM) for 24 h, in
the presence and absence of zinc sulphate (100 µM) under shaking conditions at 37 ◦C.
Absorbance of bacteria was assessed at 600 nm and bacteria number was normalised
prior to plating on blood agar plates. Plates were incubated at 37 ◦C and haemolysis
was assessed at 24 h alongside Staphylococcus aureus as a positive control [69]. Images of
the plates were taken using UVI-Tec imager (Uvitec Ltd., Cambridge, UK). To perform
semi-quantitative analysis of the haemolysis assay, images were assessed using ImageJ
1.51 s (http://imagej.nih.gov/ij, 19 March 2021). For each streak, the area of the bacteria
and the haemolysis area on the blood agar plates was measured in relative units and the
haemolytic potential was calculated as the haemolysis area minus the bacteria area.
4.6. Adhesion Assay
Adhesion of the model gut bacteria to Caco-2 cells following artificial sweetener
exposure was measured as previously described [70] with some modifications. Caco-2
cells were seeded on 24-well tissue culture plates (7.5 × 104 cells/well) and incubated in
humidified condition (90%) at 37 ◦C and 5% CO2 for 48 h, following exposure to artificial
sweeteners for 24 h. Meanwhile, a single colony of E. coli and E. faecalis was inoculated
into 10 mL of respective media supplemented with the artificial sweeteners in the presence
or absence of zinc sulphate, or vehicle (ddH2O) and incubated overnight at 37 ◦C with
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shaking at 150 rpm. Bacteria were then washed twice with 500 µL serum and antibiotic-free
EMEM media by centrifuging at 4000 rpm (2683× g) for 10 min at 37 ◦C (accuSpinTM
1R, Fisher Scientific, Thermo Electron Corporation LED GmbH, Osterode, Germany) and
re-suspended in EMEM without antibiotics.
Caco-2 cell monolayers were washed twice with 500 µL PBS, and then EMEM (490 µL;
without antibiotics) was added to each well. The total number of adherent Caco-2 cells
was measured by performing a cell count. Bacterial suspension (10 µL) was added on the
Caco-2 cells at a multiplicity of infection (MOI) 1:300 for an infection incubation time of
1 h. After the infection period, the cells were washed twice with 500 µL of sterile PBS,
the Caco-2 cells were lysed with 500 µL of 0.5% Triton X-100 by pipetting up and down.
The number of viable bacteria was determined by spread-plating serial dilutions of the
cell suspension on respective solid media, followed by overnight incubation at 37 ◦C and
counting colony forming units. Bacterial adhesion was expressed as ratio of total bacteria
attached per viable Caco-2 cells (normalised to 1). Each assay was performed in triplicate
with the successive passage of Caco-2 cells.
4.7. Invasion Assay
Caco-2 cells were seeded on 24-well tissue culture plates at a density of 7.5 × 104 cells/well
for 36 h followed by exposure to artificial sweeteners for 24 h at 37 ◦C in humidified
condition with 5% CO2. The cell monolayer was washed twice with 500 µL sterile PBS and
490 µL fresh EMEM media without antibiotics was added. Bacterial invasion of Caco-2 cells
was measured using the antibiotic protection assay previously described [71] with some
modifications. Bacteria were exposed to the artificial sweeteners and prepared for infection,
as described in Section 4.6. The number of adhered Caco-2 cells that were subjected to
bacterial infection was determined by performing a cell count. Caco-2 cell monolayer was
infected with bacteria at MOI 1:300 for 1 h at 37 ◦C. The monolayer was washed once
with 500 µL PBS and fresh cell culture medium (500 µL) was added containing 100 µg/mL
gentamicin for E. coli and 100 µg/mL gentamicin along with 50 µg/mL ampicillin for
E. faecalis and incubated at 37 ◦C for 30 min to kill the external-adhered bacteria [71]. The
cell monolayer was washed twice with PBS and then lysed with 0.5% Triton X-100 in PBS.
The number of viable colony-forming units were determined by diluting and plating
the samples onto solid media and incubating overnight at 37 ◦C. The results were expressed
as the ratio of intracellular bacteria compared with the control (normalized to 1). Each
assay was performed in triplicate with the successive passage of Caco-2 cells.
4.8. Cytotoxicity Assay
The cytotoxic effect of AS-mediated bacterial metabolites on intestinal epithelial cells
was performed following the protocol previously described [72] with modifications, and
cell viability was measured by using the Cell Counting Kit-8 (CCK-8), as per manufacturer’s
guidelines. Caco-2 cells were grown on 96-well plates (1 × 104 cells/well) and incubated
for 48 h at 37 ◦C in humidified condition with 5% CO2. Simultaneously, E. coli or E. faecalis
was grown in 10 mL of respective liquid media supplemented with 100 µM of artificial
sweeteners with or without 100 µM/mL zinc sulphate or vehicle for 24 h. The cultures
were centrifuged at 4000 rpm (2683× g) for 15 min at 4 ◦C and supernatant was collected,
filter-sterilized (0.22 µM membranes; Millipore, USA). 50 µL of the soluble bacterial factors
(supernatant) and 50 µL EMEM without antibiotics was added to the pre-washed (with
100 µL of sterile PBS) Caco-2 cell monolayer. Cells were incubated for 24 h followed by
measurement of cell viability using CCK-8 reagent assessed as absorbance at 450 nm using
a microplate reader (Tecan SunriseTM, Denmark, Switzerland).
4.9. Statistical Analysis
All the quantitative data was collected as Excel (Microsoft Office) files. The average
of triplicates for each study were analysed as n = 1 with n = 5–6 for all studies except the
haemolysis assay. Data were analysed using GraphPad Prism 7. Statistical analysis was
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performed using either a one-way ANOVA or a two-way ANOVA, with Tukey multiple
comparisons post-hoc test where relevant. Significance was reached when p < 0.05.
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